Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERAS-007 or ERAS-601 + Gilteritinib in R/R FLT3-Mutated AML
NCT05279859Phase 2Withdrawn
- Sponsor
- Erasca
- Start
- Mar 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ERAS-007 and ERAS-601 in acute myeloid leukemia (AML) (4 arms), sponsored by Erasca. Primary endpoints: Dose Limiting Toxicities at Day 29, Maximum Tolerated Dose at Day 29 and 2 more. Planned start Mar 2022; status: withdrawn.
02
Drugs
ERAS-007ERAS-601
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05279859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279859.